HRTX Heron Therapeutics
- 1.580
- +0.050+3.27%
- 1.540
- -0.040-2.53%
Heron Therapeutics News
Needham Maintains Heron Therapeutics(HRTX.US) With Buy Rating, Maintains Target Price $4
Analysts Offer Insights on Healthcare Companies: Biohaven Ltd. (BHVN), Arrowhead Pharmaceuticals (ARWR) and Heron Therapeutics (HRTX)
Heron Therapeutics Secures Revenue Stream With Court Ruling, Analyst Recommends Buy
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Sector Update: Health Care Stocks Steady Pre-Bell Wednesday
Traders Await Powell Comments as US Equity Futures Post Premarket Gains
Heron Therapeutics Patent Victory Removes 'Major Overhang,' Says Northland
Top Premarket Gainers
Heron Therapeutics Price Target Maintained With a $4.00/Share by Needham
Trending Stocks Today | CN Energy Surges 94.04% Pre-Market
Why Marvell Technology Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
Heron Therapeutics Shares Surge on Favorable Cinvanti Patent Ruling
Heron Therapeutics' Patent of Cinvanti Found Valid by Delaware District Court
Express News | Heron Therapeutics-Will Seek Order From U.S. Court Prohibiting Fresenius From Launching Its Generic Cinvanti Until After Expiration of Patents in 2035
Express News | Heron Therapeutics Inc: U.S. District Court Upholds Validity of Cinvanti Patents
Northland Securities Maintains Heron Therapeutics(HRTX.US) With Buy Rating, Maintains Target Price $9
Heron Therapeutics (HRTX) Gets a Buy From Northland Securities
Starbucks To $77? Here Are 10 Top Analyst Forecasts For Wednesday
Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Institutional Investors Lost 28% Over the Past Week but Have Profited From Longer-term Gains
Benign Growth For Heron Therapeutics, Inc. (NASDAQ:HRTX) Underpins Stock's 30% Plummet
No Data